Recursion Pharmaceuticals

Yahoo Finance • 10 days ago

The Future of Intoxication Detection May Be in Your Voice

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safe... Full story

Yahoo Finance • 14 days ago

Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data... Full story

Yahoo Finance • 21 days ago

Recursion Announces Board Transition

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current te... Full story

Yahoo Finance • 25 days ago

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This... Full story

Yahoo Finance • 29 days ago

Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working?

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is accelerating its drug development programs and unlocking cost-savings opportunities thanks to i... Full story

Yahoo Finance • last month

Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the best medical AI stocks to buy now. On March 31, Recursion moved to supercharge its AI-driven drug discovery platform through an expanded partnership with Citeline. Citeline is a lead... Full story

Yahoo Finance • 2 months ago

Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX)

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and development platform, aiming to improv... Full story

Yahoo Finance • 2 months ago

1 Beaten-Down AI Stock to Buy and 1 to Avoid

Key Points Alphabet is already a leader in AI and boasts attractive growth avenues beyond this industry. Recursion Pharmaceuticals has a long way to go before demonstrating that its approach works. 10 stocks we like better than Alphabet ›... Full story

Yahoo Finance • 2 months ago

2 AI Healthcare Stocks to Buy Right Now

While the advent of artificial intelligence (AI) has obviously changed the world, not every utilization of AI has necessarily made the world a better place. Indeed, a recent survey from PwC indicates that 56% of CEOs aren't yet seeing any... Full story

Yahoo Finance • 2 months ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

The past several weeks have been challenging ones for the overall market. But they've been downright miserable ones for most artificial intelligence (AI) stocks. Microsoft shares are down more than 20% from last year's peak, for instance,... Full story

Yahoo Finance • 2 months ago

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026

Key Points In retrospect, it’s clear that most AI stocks’ inflated valuations were never fully justified. The technology isn’t going away, though. It’s evolving into one with more practical and marketable uses. Some companies are better p... Full story

Yahoo Finance • 2 months ago

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Key Points Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.10 s... Full story

Yahoo Finance • 2 months ago

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the sh... Full story

Yahoo Finance • 2 months ago

Can This AI Stock Bounce Back in 2026?

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of the bigger names in the field, like Nvidia, have seen their shares soar in recent years, while other, smaller one... Full story

Yahoo Finance • 3 months ago

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) but lowered the price target... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full year 2025, highlighting a pivotal transiti... Full story

Yahoo Finance • 3 months ago

Recursion (RXRX) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Feb. 25, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Najat KhanChief Financial Officer — Ben TaylorChief Scientific Officer — Dave Hallett Need a quote from a Motley Foo... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Platform Validation Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to transl... Full story

Yahoo Finance • 3 months ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing wi... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory filings indicated that Nvidia had divested a... Full story